These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37130060)

  • 1. Medication for Opioid Use Disorder During Pregnancy - Maternal and Infant Network to Understand Outcomes Associated with Use of Medication for Opioid Use Disorder During Pregnancy (MAT-LINK), 2014-2021.
    Miele K; Kim SY; Jones R; Rembert JH; Wachman EM; Shrestha H; Henninger ML; Kimes TM; Schneider PD; Sivaloganathan V; Sward KA; Deshmukh VG; Sanjuan PM; Maxwell JR; Seligman NS; Caveglia S; Louis JM; Wright T; Bennett CC; Green C; George N; Gosdin L; Tran EL; Meaney-Delman D; Gilboa SM
    MMWR Surveill Summ; 2023 May; 72(3):1-14. PubMed ID: 37130060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of Racial and Ethnic Disparities in the Use of Medication to Treat Opioid Use Disorder Among Pregnant Women in Massachusetts.
    Schiff DM; Nielsen T; Hoeppner BB; Terplan M; Hansen H; Bernson D; Diop H; Bharel M; Krans EE; Selk S; Kelly JF; Wilens TE; Taveras EM
    JAMA Netw Open; 2020 May; 3(5):e205734. PubMed ID: 32453384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Racial/ethnic differences in medication for addiction treatment for opioid use disorders among pregnant women in treatment facilities supported by state funds.
    Kitsantas P; Aljoudi SM; Baker KM; Peppard L; Oh KM
    J Subst Use Addict Treat; 2023 May; 148():208960. PubMed ID: 37102193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors associated with receipt of medication for opioid use disorder among pregnant individuals entering treatment programs in the U.S.
    Curran L; Manuel J
    Int J Drug Policy; 2024 Apr; 126():104342. PubMed ID: 38479161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Core state preconception health indicators - pregnancy risk assessment monitoring system and behavioral risk factor surveillance system, 2009.
    Robbins CL; Zapata LB; Farr SL; Kroelinger CD; Morrow B; Ahluwalia I; D'Angelo DV; Barradas D; Cox S; Goodman D; Williams L; Grigorescu V; Barfield WD;
    MMWR Surveill Summ; 2014 Apr; 63(3):1-62. PubMed ID: 24759729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Medication for Opioid Use Disorder Among US Adolescents and Adults With Need for Opioid Treatment, 2019.
    Mauro PM; Gutkind S; Annunziato EM; Samples H
    JAMA Netw Open; 2022 Mar; 5(3):e223821. PubMed ID: 35319762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Explaining Racial-ethnic Disparities in the Receipt of Medication for Opioid Use Disorder during Pregnancy.
    Gao YA; Drake C; Krans EE; Chen Q; Jarlenski MP
    J Addict Med; 2022 Nov-Dec 01; 16(6):e356-e365. PubMed ID: 35245918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The MATernaL and Infant NetworK to Understand Outcomes Associated with Treatment of Opioid Use Disorder During Pregnancy (MAT-LINK): Surveillance Opportunity.
    Tran EL; Kim SY; England LJ; Green C; Dang EP; Broussard CS; Fehrenbach N; Hudson A; Yowe-Conley T; Gilboa SM; Meaney-Delman D
    J Womens Health (Larchmt); 2020 Dec; 29(12):1491-1499. PubMed ID: 33227221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disparities in receipt of medications for opioid use disorder among pregnant women.
    Henkhaus LE; Buntin MB; Henderson SC; Lai P; Patrick SW
    Subst Abus; 2022; 43(1):508-513. PubMed ID: 34270396
    [No Abstract]   [Full Text] [Related]  

  • 11. Perceptions around medications for opioid use disorder among a diverse sample of U.S. adults.
    Jaffe K; Slat S; Chen L; Macleod C; Bohnert A; Lagisetty P
    J Subst Use Addict Treat; 2024 Aug; 163():209361. PubMed ID: 38703949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surveillance for Violent Deaths - National Violent Death Reporting System, 48 States, the District of Columbia, and Puerto Rico, 2021.
    Nguyen BL; Lyons BH; Forsberg K; Wilson RF; Liu GS; Betz CJ; Blair JM
    MMWR Surveill Summ; 2024 Jul; 73(5):1-44. PubMed ID: 38980822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioid use disorder incidence and treatment among incarcerated pregnant women in the United States: results from a national surveillance study.
    Sufrin C; Sutherland L; Beal L; Terplan M; Latkin C; Clarke JG
    Addiction; 2020 Nov; 115(11):2057-2065. PubMed ID: 32141128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Perceived Access and Treatment Knowledge on Medication Preferences for Opioid Use Disorder.
    Jaffe K; Patel S; Chen L; Slat S; Bohnert A; Lagisetty P
    Subst Use Addctn J; 2024 Oct; 45(4):706-715. PubMed ID: 38828548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Duration of medication for opioid use disorder during pregnancy and postpartum by race/ethnicity: Results from 6 state Medicaid programs.
    Austin AE; Durrance CP; Ahrens KA; Chen Q; Hammerslag L; McDuffie MJ; Talbert J; Lanier P; Donohue JM; Jarlenski M
    Drug Alcohol Depend; 2023 Jun; 247():109868. PubMed ID: 37058829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variation in Opioid Agonist Dosing in Clinical Trials by Race and Ethnicity.
    Ross RK; Inose S; Shulman M; Nunes EV; Zalla LC; Burlew AK; Rudolph KE
    JAMA Netw Open; 2024 Oct; 7(10):e2436612. PubMed ID: 39365581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Racial and Ethnic Disparities in Maternal and Infant Outcomes Among Opioid-Exposed Mother-Infant Dyads in Massachusetts (2017-2019).
    Peeler M; Gupta M; Melvin P; Bryant AS; Diop H; Iverson R; Callaghan K; Wachman EM; Singh R; Houghton M; Greenfield SF; Schiff DM
    Am J Public Health; 2020 Dec; 110(12):1828-1836. PubMed ID: 33058701
    [No Abstract]   [Full Text] [Related]  

  • 18. Integrating Opioid Use Disorder Treatment Into Primary Care Settings.
    Austin EJ; Chen J; Briggs ES; Ferro L; Barry P; Heald A; Merrill JO; Curran GM; Saxon AJ; Fortney JC; Ratzliff AD; Williams EC
    JAMA Netw Open; 2023 Aug; 6(8):e2328627. PubMed ID: 37566414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disparities in Preconception Health Indicators - 
Behavioral Risk Factor Surveillance System, 2013-2015, and Pregnancy Risk Assessment Monitoring System, 2013-2014.
    Robbins C; Boulet SL; Morgan I; D'Angelo DV; Zapata LB; Morrow B; Sharma A; Kroelinger CD
    MMWR Surveill Summ; 2018 Jan; 67(1):1-16. PubMed ID: 29346340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disparities in opioid use disorder-related hospital use among postpartum Virginia Medicaid members.
    Martin CE; Britton E; Shadowen H; Bachireddy C; Harrell A; Zhao X; Cunningham P
    J Subst Use Addict Treat; 2023 Feb; 145():208935. PubMed ID: 36880911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.